ArticleBreast (Edinburgh, Scotland)2026
Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients with advanced breast cancer (ABC), standard-of-care (SOC) treatment in first line (1L) with CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) is well established. However, data on treatment patterns in second line (2L), where the treatment landscape is evolving, are lacking. This large real-world study investigated treatment sequencing from 1L to 2L in patients with HR+/HER2- ABC in the post-CDK4/6i era.
methodsData leveraged the Adelphi ABC Disease Specific Programme (DSP)™, a cross-sectional survey conducted in Europe and the United States between July 2022 and March 2023. Physicians provided data for consecutively consulting patients, including current and historic clinical status, treatment sequencing and biomarker testing history. All analyses were descriptive.
resultsData for 767 patients with HR+/HER2- ABC receiving 2L treatment at data collection were analyzed. In 2L, 31.6% received chemotherapy-based regimens, 17.7% received ET monotherapy, 21.5% received CDK4/6i + ET, and 26.3% received a targeted therapy (mTOR/PARP/PI3K inhibitors). Of those receiving 2L, 58% previously received a CDK4/6i regimen in 1L, in line with treatment guidance, while 21% received chemotherapy. Use of targeted therapies in 2L was driven by biomarker testing. Country/region-specific variation in biomarker testing and treatments were likely due to differences in local guidance and practice.
conclusionThis study provides insights into treatment sequencing in patients with HR+/HER2- ABC who progress to 2L in the post-CDK4/6i era. For patients without targetable mutations, there is no clear SOC at 2L and treatment options are limited. New treatments may further shape this developing landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.